Monday, September 25, 2017 9:18:28 PM
Short to mid term products are entering an IMS market value
of $6 + Billion Dollar$
Bright future ahead for ELTP
Elite's Current Marketed Products and Pipeline is growing rapidly ! Fully developed its worth Billion$
Start watching for the undisclosed drug filings.
$$$$$$$$$$$$
Elite working on 7 AD opiods concurrently
$Generic Products$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
1. Hydromorphone Hydrochloride
8 mg Tablets
Dilaudid®
Pain
2. Naltrexone Hydrochloride
50 mg Tablets
Revia®
Opioid Antagonist
3. Phentermine HCl
37.5 mg Tablets
Adipex-P®
Bariatric
4. Phentermine HCI
15 mg and 30 mg Capsules
Adipex-P®
Bariatric
5. Phendimetrazine Tartrate
35 mg Tablets, USP
Bontril®
Bariatric
6. Isradipine
2.5 mg and 5 mg Capsules
N/A
Cardiovascular
7. Hydroxyzine HCI
10 mg, 25 mg, 50 mg Tablets
Atarax®, Vistaril®
Antihistamine
8. Dantrolene Sodium
25 mg, 50 mg and 100 mg Capsules *
Dantrium®
Skeletal Muscle Relaxant
9. Loxapine
5 mg, 10 mg, 25 mg, 50 mg Capsules *
N/A
Antipsychotic
10. Additional Approved ANDA's *
Undisclosed
Undisclosed
* pending manufacturing site transfer
11. Trimipramine
$BRANDED PRODUCTS$$
Commercial Product
Therapeutic Category
Partner
12. Lodrane D®
OTC Allergy
Valeant Pharmaceuticals International, Inc.
$CONTRACT MANUFACTURING$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
Partner
13. Methadone Hydrochloride
10 mg Tablets
Dolophine®
Pain
Ascend Laboratories, LLC
$GENERIC PIPELINE$$
Programs Under Development
Branded Product Equivalent
Therapeutic Category
Development Stage
14. ELI-300 Opioid
Undisclosed
Pain
Early Development
15. ELI-301 Opioid
Undisclosed
Pain
Early Development
16. Oxycodone HCl and Acetaminophen, USP 325 mg
5 mg, 7.5 mg, 10 mg Tablets
Percocet
Pain
Pending FDA Approval
17. Hydrocodone bitartrate and Acetaminophine tablets, 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets
Norco
Pain
Pending FDA Approval
18. Elite/SunGen Generic #1
Undisclosed
CNS Stimulant
In Development
19. Elite/SunGen Generic #2
Undisclosed
CNS Stimulant
In Development
20. Elite/SunGen Generic #3
Undisclosed
Beta-Blocker
In Development
21. Elite/SunGen Generic #4
Undisclosed
Beta-Blocker
In Development
22. Elite/SunGen Generic #5
Undisclosed
Anti-depressant
In Development
23. Elite/SunGen Generic #6
Undisclosed
Antibiotic #1
In Development
24. Elite/SunGen Generic #7
Undisclosed
Antibiotic #2
In Development
25. Elite/SunGen Generic #8
Undisclosed
Antispasmodic
In Development
26. Generic Troxyca
Pain
27. Generic Embeda
Pain
28. Generic OxyContin
29. Generic Opana Oxymorphone
Pain
$BRANDED PIPELINE$$
Development Stage
Partner
30. $equestOx™ (ELI-200) Opioid
Pain
NDA Submitted
PDUFA date: July 14, 2016
Epic Pharma LLC
31. ELI-201 ER Opioid
Troxyca equivalent
Pain
Pivotal Bio-equivalence
32. ELI-202 Opioid
Pain
Pivotal Bio-equivalence
33. ELI-216 Opioid ER 24hr (once/day)
Pain
Process Development
34. ELI-400 Opioid
Pain
Process Development
35. ELI-500 Opioid
Pain
Process Development
36. ELI-501 Opioid
Pain
Early Development
37. ELI-600 Opioid
Pain
Process development ELTP
38. Chinese ADF opiod
39. Canadian ADF opiod
40. European ADF opiod
$ELTP
ELTP
You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM